-0.71   (-11.25%)
After Hours: 5.75 0.15 (2.68%)
Volume (24h) Market Cap. Day Range 52w Range
2.91M 865.82M 5.59 - 6.54 0.73 - 13.40
Oct-16-20 04:41PM Why Adaptimmune Therapeutics Stock Is Sinking TodayMotley Fool
Oct-15-20 08:40PM Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS TrialGlobeNewswire
Oct-13-20 04:04PM Hedge Funds Have Never Been This Bullish On Adaptimmune Therapeutics plc (ADAP)Insider Monkey
Oct-09-20 10:18AM What Kind Of Shareholders Hold The Majority In Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Shares?Simply Wall St.
Aug-28-20 02:30PM Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for PatientsGlobeNewswire
Aug-11-20 04:00PM All You Need to Know About Adaptimmune Therapeutics PLC (ADAP) Rating Upgrade to BuyZacks
Aug-10-20 11:40AM Announcing: Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Soared An Exciting 367% In The Last YearSimply Wall St.
11:25AM Did The Underlying Business Drive Adaptimmune Therapeutics' (NASDAQ:ADAP) Lovely 367% Share Price Gain?Simply Wall St.
Aug-06-20 11:30AM Adaptimmune Reports Q2 Financial Results and Business UpdateGlobeNewswire
Jul-23-20 08:00PM Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial SarcomaGlobeNewswire
Jul-22-20 12:00PM Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020GlobeNewswire
Jul-05-20 06:25PM Should You Buy Adaptimmune Therapeutics plc (ADAP)?Insider Monkey
Jun-23-20 03:26PM Edited Transcript of ADAP earnings conference call or presentation 14-May-20 12:00pm GMTThomson Reuters StreetEvents
Jun-17-20 01:33PM Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?Zacks
12:52PM How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong IndustryZacks
Jun-12-20 10:30AM Is Adaptimmune Therapeutics a Buy?Motley Fool
Jun-08-20 02:30PM Why Adaptimmune Therapeutics Stock Crushed It in MayMotley Fool
Jun-04-20 02:45PM Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary SharesGlobeNewswire
Jun-02-20 08:37AM Adaptimmune Announces $11/ADS Pricing; Stock Now Up Over 850% YTDSmarterAnalyst
04:38AM Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?Zacks
Jun-02-20 01:39AM Adaptimmune Therapeutics plc Prices Public Offering of American Depositary SharesGlobeNewswire
Jun-01-20 04:51PM Why Adaptimmune Therapeutics Stock Sank and Then Quickly Rebounded TodayMotley Fool
03:01PM Party Time: Brokers Just Made Major Increases To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Earnings ForecastsSimply Wall St.
Jun-01-20 01:38PM Company News for June 1, 2020Zacks
10:09AM Adaptimmune's stock tumbles after plans for public stock offeringMarketWatch
Jun-01-20 10:00AM Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary SharesGlobeNewswire
08:15AM Adaptimmune Spikes 127% Post-ASCO; Analyst Triples Price TargetSmarterAnalyst
May-29-20 09:08PM The Dow Slipped 18 Points Because Trump Pulled His Punches on
06:20PM Here's Why Adaptimmune Therapeutics Is Rocketing Higher TodayMotley Fool
May-29-20 02:32PM Traders Sift Through Virtual Cancer Meeting’s Winners and LosersBloomberg
02:24PM Adaptimmune Stock Doubles on Positive Cancer Drug
May-29-20 11:30AM SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ CancerGlobeNewswire
May-19-20 11:02AM Where Will Adaptimmune Be in 5 Years?Motley Fool
May-15-20 12:27PM Edited Transcript of ADAP earnings conference call or presentation 14-May-20 12:00pm GMTThomson Reuters StreetEvents
May-14-20 04:00PM Adaptimmune Therapeutics PLC (ADAP) Q1 2020 Earnings Call TranscriptMotley Fool
12:55PM Recap: Adaptimmune Therapeutics Q1 EarningsBenzinga
May-14-20 11:30AM Adaptimmune Reports Q1 Financial ResultsGlobeNewswire
May-12-20 12:00PM SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual MeetingGlobeNewswire
10:07AM What Kind Of Share Price Volatility Should You Expect For Adaptimmune Therapeutics plc (NASDAQ:ADAP)?Simply Wall St.
Apr-29-20 12:00PM Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020GlobeNewswire
Apr-28-20 04:00PM What Makes Adaptimmune Therapeutics PLC (ADAP) a New Strong Buy StockZacks
12:00PM Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal ProductsGlobeNewswire
Mar-21-20 02:40AM Edited Transcript of ADAP earnings conference call or presentation 27-Feb-20 1:00pm GMTThomson Reuters StreetEvents
Mar-11-20 03:35PM Passage Bio's IPO tops out at $248.4M after options exercisedAmerican City Business Journals
Feb-29-20 01:31PM Earnings Update: Adaptimmune Therapeutics plc Just Reported And Analysts Are Boosting Their EstimatesSimply Wall St.
Feb-27-20 12:30PM Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business UpdateGlobeNewswire
11:00AM Adaptimmune Therapeutics Plc to Host Earnings CallACCESSWIRE
Feb-24-20 08:15PM After leadership overhaul, Adaptimmune targets first cell therapy product launchAmerican City Business Journals
Feb-20-20 09:00PM Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020GlobeNewswire
Feb-18-20 01:00PM Adaptimmune Announces Appointment of Gavin Wood as Chief Financial OfficerGlobeNewswire
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Cap:    |  Volume (24h):